Next-generation sequencing, or NGS, is the technology that reads DNA at the speed and cost that make the “Imperium” pitch possible. It is the read step of the DNA stack, and it is the reason a genome that once cost millions now costs a few hundred dollars. This explainer walks through what NGS actually is, how it differs from the older method it replaced, and which companies lead the market.
What Is Next-Generation Sequencing?
NGS is a family of techniques that decode DNA by reading millions or billions of fragments in parallel at once. Where older methods read DNA one stretch at a time, NGS floods a machine with many small pieces of DNA, reads them all simultaneously, and then uses software to reassemble the result into the full sequence.
The “parallel” part is the whole point. By reading many fragments at the same time, NGS collapses the time and cost of sequencing by orders of magnitude, which is precisely what turned genome reading from a national project into a routine lab procedure. That throughput is the foundation the pitch’s “DNA is getting faster and cheaper” argument stands on.
NGS vs. First-Generation Sequencing
The older method NGS displaced is called Sanger sequencing, named for Frederick Sanger, and it is still used today for small, high-accuracy jobs like confirming a single short sequence. Sanger reads one fragment at a time, so it is slow and expensive at genome scale, but it is extremely accurate on short stretches.
NGS trades a little of that per-read simplicity for enormous parallelism. It is not that NGS is less accurate overall, but that it works at a completely different scale: a single NGS run can read an entire human genome in about a day, where the first human genome took well over a decade. That scale shift is the practical meaning of the technology, and it is what the Imperium thesis leans on when it says reading DNA has become cheap enough to matter.
Short Reads and Long Reads
Within NGS, the field splits into two main approaches. Short-read sequencing, the dominant and cheapest method, reads DNA in small fragments and reassembles them. It is fast and inexpensive but can struggle with long, repetitive regions of the genome, which get ambiguous when chopped into tiny pieces.
Long-read sequencing reads much longer fragments at once, which resolves those tricky regions cleanly but costs more per read. The two approaches are complementary, and the market leaders have sorted themselves along that line. For a plain-language comparison of the two, our DNA synthesis explainer sits on the other side of the stack, covering the write step that sequencing feeds into.
The Leaders
The read layer has a clear structure. Illumina is the dominant short-read player, the company whose machines sit in most sequencing labs, with the scale and installed base that come with being the default choice. Pacific Biosciences leads in long reads, the approach that handles the regions short reads miss, and it has carved out a smaller but growing niche.
Those two, plus the single-cell specialist 10x Genomics, anchor the read layer of the DNA economy. They are the suppliers and neighbors that make the pitch’s picks possible rather than the picks themselves. Twist Bioscience, the pitch’s silicon-layer pick, is both a partner and a customer of Illumina, so the read and write layers are commercially linked. Our Illumina stock piece and Twist Bioscience stock piece cover the leaders and the anchor name in detail.
How NGS Feeds the Imperium Thesis
The connection between NGS and the Imperium pitch is direct. Reading DNA is the input that makes writing it useful, and the cost collapse NGS delivered is what turned the write step from a scientific curiosity into a commercial opportunity. Once reading a genome is cheap, designing against it becomes practical, and once design is practical, synthesis becomes valuable.
The pitch spends its energy on the write layer for a reason. The read layer has already matured, and its cost decline is largely priced in. The earlier, faster-moving opportunity sits one step downstream, in the companies that write the DNA the sequencers have just finished reading. That is the arc of the thesis in a sentence, and it is why understanding NGS is the right first step for anyone sizing up the pitch.
Where NGS Is Headed
The next phase of NGS is about reach rather than raw speed. Sequencing has moved out of research labs and into the clinic, into population-scale screening, and into recurring applications like cancer monitoring, where a patient’s DNA is read repeatedly over time. Those markets are larger than the research market that built the current leaders, and they reward whoever can deliver accuracy at the lowest per-sample cost.
None of that changes the pitch’s central judgment, which is that the read layer has already matured and the more interesting economics now sit one step downstream. Reading DNA is the settled foundation; writing it is where the cost curve is still bending and where the winners are still being sorted. Understanding NGS is the first step, but it is not the last.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.